NYSE:BHC (Canada) Also trade in: Canada Germany Mexico Switzerland UK

Bausch Health Companies Inc

$ 23.72 0.71 (3.09%)
On watch
Volume: 4,480,706 Avg Vol (1m): 4,011,337
Market Cap $: 8.37 Bil Enterprise Value $: 32.23 Bil
P/E (TTM): 0.00 P/B: 3.06
Earnings Power Value -42.12
Net Current Asset Value -72.82
Tangible Book -63.88
Projected FCF 54.38
Median P/S Value 77.89
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 37.7
DCF (Earnings Based) -126.48
YTD (-%)

Financial Strength : 3/10

Current vs industry vs history
Cash-to-Debt 0.03
Equity-to-Asset 0.08
Debt-to-Equity 8.89
Debt-to-EBITDA 65.69
Interest Coverage 0.30
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -0.06
DISTRESS
GREY
SAFE
Beneish M-Score -2.98
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 1.84%
WACC 2.47%

Profitability & Growth : 8/10

Current vs industry vs history
Operating Margin % 6.00
Net Margin % -50.40
ROE % -108.67
ROA % -12.21
ROC (Joel Greenblatt) % -178.47
3-Year Total Revenue Growth Rate -7.70
3-Year Total EBITDA Growth Rate -56.00
3-Year EPS w/o NRI Growth Rate -138.80
N/A

» BHC's 30-Y Financials

Financials (Next Earnings Date: 2019-05-06)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:BHC

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 3741
Compare BOM:532321 SZSE:002773 SZSE:000423 SHSE:600566 HKSE:00867 TSE:4530 SZSE:002001 BSP:HYPE3 SHSE:600521 NYSE:CTLT NSE:AUROPHARMA BOM:500257 SHSE:603858 SZSE:000513 SZSE:300142 TSE:4506 BOM:500124 TSE:4516 SZSE:300601 SHSE:600535
Traded in other countries BVF.Germany VRX.Switzerland 0QYW.UK
Address 2150 St. Elzear Blvd. West, Laval, QC, CAN, H7L 4A8
Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia.

Ratios

Current vs industry vs history
Forward PE Ratio 5.89
N/A
PB Ratio 3.06
PS Ratio 1.04
Price-to-Free-Cash-Flow 6.74
Price-to-Operating-Cash-Flow 5.69
EV-to-EBIT -13.43
EV-to-EBITDA 86.37
EV-to-Revenue 3.93
Current Ratio 1.10
Quick Ratio 0.85
Days Inventory 153.88
Days Sales Outstanding 83.09
Days Payable 65.27

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -0.80

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 0.44
Price-to-Median-PS-Value 0.30
Earnings Yield (Joel Greenblatt) % -7.45
Forward Rate of Return (Yacktman) % -8.71

More Statistics

Revenue (TTM) (Mil) $ 8,380
EPS (TTM) $ -12.15
Beta 2.18
Volatility % 51.99
52-Week Range $ 16.98 - 28.45
Shares Outstanding (Mil) 157.5

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA N
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy Y
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y